Demographic, histology and follow-up data for n=342 patients admitted between 1 November 2014 and 30 November 2015 with primary lung cancer, by index CT scan findings
| All | No endobronchial disease | Endobronchial disease (no CAO) | CAO | |
| N | 342 (100%) | 212 (62%) | 85 (25%) | 45 (13%) |
| Age (years) | 71.9 (64.7–78.2) | 72.3 (64.9–78.6) | 70.8 963.8–78.8) | 71.5 (65.2–76.7) |
| Gender (female) | 163 (48%) | 102 (48%) | 38 (45%) | 23 (51%) |
| Cell type* | ||||
| Adenocarcinoma | 132 (54%) | 90 (64%) | 30 (45%) | 11 (31%) |
| Squamous | 61 (25%) | 28 (20%) | 20 (30%) | 13 (37%) |
| NSCLC other | 10 (4%) | 4 (3%) | 2 (3%) | 4 (12%) |
| SCLC | 31 (13%) | 14 (10%) | 11 (16%) | 6 (17%) |
| Mixed SCLC/NSCLC | 4 (2%) | 4 (3%) | 1 (2%) | 0 (0%) |
| Carcinoid | 4 (2%) | 0 (0%) | 3 (4%) | 1 (3%) |
| Stage (TNM 7) | ||||
| Stage I | 82 (24%) | 76 (36%) | 5 (6%) | 1 (2%) |
| Stage II | 23 (7%) | 19 (9%) | 2 (2%) | 2 (4%) |
| Stage III | 84 (24%) | 37 (17%) | 30 (35%) | 15 (33%) |
| Stage IV | 153 (45%) | 80 (38%) | 43 (51%) | 27 (60%) |
| Radiological follow-up (days) | 185.5 (34.8–703.8) | 349 (81–1067) | 120 (32–324) | 43 (8–162) |
| Patients dead at final follow-up | 273 (80%) | 152 (72%) | 77 (91%) | 44 (98%) |
| Time to death (days) | 203 (62–436) | 246 (80–590) | 141 (51–335) | 96 (36–271) |
| Follow-up CAO | 15 (5%) | 8 (4%) | 7 (8%) |
Data show N (%) and median (IQR).
*Cell type total N=242–100 patients did not histology results (no endobronchial disease N=140; endobronchial disease with no CAO N=67; CAO N=35).
CAO, central airway obstruction; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; TNM, Tumour Node Metastases.